Analysis of CD271-positive NSCLC as a potential therapeutic target
| Project/Area Number |
15K19437
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
KOSAI HITOMI 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 共同研究員 (70728203)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TANAKA Nobuyuki 地方独立法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 部長 (60280872)
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 肺癌幹細胞 / 肺癌 / 扁平上皮癌 |
|---|
| Outline of Final Research Achievements |
CD271 has been shown to be a cancer stem cell marker of squamous cell carcinoma. To determine a potential role of CD271 in squamous cell carcinoma of the lung, CD271 was knock-downed by shRNA. CD271 mRNA knockdown inhibited both cell proliferation and migration. p42/44Erk inhibition as well as RhoA inhibition inhibited these malignant phenotypes. These malignant potential was delivered from the intra-cytoplasmic region of CD271. Together, CD271 is a potential target for squamous cell carcinoma type NSCLC therapy.
|
Report
(3 results)
Research Products
(2 results)
